Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 272
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

272 results for “breast-cancer” Back to intelligence hub

Search results

Page 4 of 12
  1. AUY922

    Novartis Pharmaceuticals

    Advanced HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial
  2. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial
  3. AZD5363 when combined with weekly paclitaxel.

    AstraZeneca

    Advanced or Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial
  4. Abraxane

    Duke University

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial
  5. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 mab terminated

    1 trial
  6. Ad-RTS-hIL-12 and Veledimex

    Alaunos Therapeutics

    Breast Cancer Nos Metastatic Recurrent

    phase 2 gene therapy terminated

    1 trial
  7. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  8. Amcenestrant

    Sanofi Pasteur

    Breast Cancer Metastatic

    phase 2 small molecule terminated

    1 trial
  9. Anti-HER2 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 mab terminated

    1 trial
  10. Apatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial
  11. Apatinib

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  12. Azenosertib

    Zentalis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial
  13. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial
  14. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial
  15. Bevacizumab

    BRIGHT MINDS BIOSCIENCES INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  16. Camrelizumab

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  17. Camrelizumab with vinorelbine and cisplatin

    The First People's Hospital of Lianyungang

    HER2-negative Breast Cancer

    phase 2 small molecule active

    1 trial
  18. Capecitabine

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial
  19. Capecitabine

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule active

    1 trial
  20. Capecitabine

    Vera Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial
  21. Chemotherapy+PD-1 inhibitor+8Gy x 3f

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HR+HER2- Breast Cancer

    phase 2 small molecule active

    1 trial
  22. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial
  23. DC1 Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 2 mab active

    1 trial
  24. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.